Bristol Myers Squibb reported that the company was abandoning the BCMA CAR-T therapy orva-cel and taking a $470 million write-off.

AbbVie announced the company’s latest chimeric antigen receptor (CAR)-T cell investment, a collaboration with Caribou Biosciences worth $40 million up front in cash and equity to develop two CRISPR-edited cell therapies against AbbVie-specified targets.

The U.S. Food and Drug Administration approved Bristol Myers Squibb’s Breyanzi (lisocabtagene maraleucel; liso-cel) for adults with relapsed or refractory large B-Cell lymphoma after two or more lines of systemic therapy.

Days after Bayer announced a new cell and gene therapy strategy to maximize the capabilities of some recent acquisitions, the Germany-based life sciences giant is jumping into the CAR-T space and expanding the company’s oncology focus through a collaboration with Bay Area-based Atara Biotherapeutics.

The American Society of Hematology (ASH) Annual Meeting & Exposition began December 5 with numerous presentations, abstracts and posters.

BioSpace reviewed the third-quarter 2020 financial announcements from some of the biopharma industry’s leading players.

South San Francisco-based Allogene Therapeutics released some early data from the company’s UNIVERSAL clinical trial of ALLO-715 for relapsed/refractory multiple myeloma.

Shares of Bellicum Pharmaceuticals plunged following an announcement that the company will slash 79% of employees as part of a restructuring following the developmental pause for one CAR-T program.

A new form of treatment known as CAR-T cell therapy has been making waves in the field of oncology, and clinical trials have begun for patients with Malignant Pleural Mesothelioma (MPM).

Bristol Myers Squibb and bluebird bio are eying a potential quick approval for a CAR-T treatment for multiple myeloma after the U.S. Food and Drug Administration accepted the Biologics License Application under priority review for idecabtagene vicleucel.